{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T14:43:58Z","timestamp":1764773038911,"version":"3.46.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000016","name":"US Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021704","name":"Administration for Strategic Preparedness and Response","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008872","name":"ASPR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008872","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["HHSO100201600015C"],"award-info":[{"award-number":["HHSO100201600015C"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022802","name":"HHS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022802","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Excel Scientific Solutions"},{"DOI":"10.13039\/100016469","name":"Takeda Pharmaceuticals International AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016469","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Zika virus (ZIKV) emergence in 2015\u20132016 was characterized by high attack rates and a wave of Congenital Zika Syndrome cases that affected several countries in the Americas. The sudden drop in virus transmission in the following years and the lack of a reliable correlate of protection have hampered the development of vaccines. ZIKV neutralizing antibodies (nAbs) responses to natural ZIKV infection provide insights into the potential efficacy of vaccine candidates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, we compared anti-ZIKV nAb responses generated by a ZIKV vaccine (TAK-426), to those elicited by natural ZIKV infection in participants from diverse geographic areas using the same neutralizing antibody assay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Those with a ZIKV infection (inapparent or symptomatic) exhibited higher levels of ZIKV nAbs, than TAK-426 vaccine recipients at all time points. The differences were less pronounced 1 month after TAK-426 dose 2. ZIKV nAb titers in vaccinated recipients were above the calculated threshold of protection at 1 month post-dose 2 for flavivirus (FV)-naive participants and at 1 and 6 months post-dose 2 for FV-primed participants. The kinetics of ZIKV nAbs were similar for both the natural infection and vaccination groups, exhibiting a peak, decline, and stabilization pattern; however, vaccine non-inferiority was not demonstrated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings suggest that nAbs evoked by the current phase 1 formulation and dosage of TAK-426 may not protect against a ZIKV infection in endemic countries and that a booster dose should be further evaluated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofaf707","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T12:55:10Z","timestamp":1763470510000},"source":"Crossref","is-referenced-by-count":0,"title":["Zika Virus Neutralizing Antibody Responses Elicited by Vaccination or Infection"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6262-8784","authenticated-orcid":false,"given":"Claudia M","family":"Galindo","sequence":"first","affiliation":[{"name":"Vaccines Business Unit, Takeda Vaccines Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Ling","sequence":"additional","affiliation":[{"name":"Vaccines Business Unit, Takeda Vaccines Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eloi","family":"Kpamegan","sequence":"additional","affiliation":[{"name":"Vaccines Business Unit, Takeda Vaccines Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo J M","family":"Nascimento","sequence":"additional","affiliation":[{"name":"Vaccines Business Unit, Takeda Vaccines Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erick","family":"Perez-Guzman","sequence":"additional","affiliation":[{"name":"Vaccines Business Unit, Takeda Vaccines Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan P Aguilar","family":"Ticona","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Oswaldo Cruz, Instituto Gon\u00e7alo Moniz , Salvador ,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai Fern","family":"Chan","sequence":"additional","affiliation":[{"name":"Vaccines Business Unit, Takeda Pharmaceuticals International ,","place":["Singapore"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priscila","family":"Castanha","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Microbiology, University of Pittsburgh , Pittsburgh, Pennsylvania ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7984-1707","authenticated-orcid":false,"given":"Darunee","family":"Buddhari","sequence":"additional","affiliation":[{"name":"WRAIR-AFRIMS, Department of Virology , Bangkok ,","place":["Thailand"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Farmer","sequence":"additional","affiliation":[{"name":"WRAIR-AFRIMS, Department of Virology , Bangkok ,","place":["Thailand"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Fernandez","sequence":"additional","affiliation":[{"name":"WRAIR-AFRIMS, Department of Virology , Bangkok ,","place":["Thailand"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Whitney R","family":"Baldwin","sequence":"additional","affiliation":[{"name":"Vaccines Business Unit, Takeda Vaccines Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maima","family":"Kaiser","sequence":"additional","affiliation":[{"name":"Vaccines Business Unit, Takeda Vaccines Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesuina","family":"Fernandes","sequence":"additional","affiliation":[{"name":"Vaccines Business Unit, Takeda Vaccines Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Zahralban-Steele","sequence":"additional","affiliation":[{"name":"Vaccines Business Unit, Takeda Vaccines Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Brinkman","sequence":"additional","affiliation":[{"name":"Vaccines Business Unit, Takeda Vaccines Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Rindfleisch","sequence":"additional","affiliation":[{"name":"Vaccines Business Unit, Takeda Vaccines Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelley J","family":"Moss","sequence":"additional","affiliation":[{"name":"Vaccines Business Unit, Takeda Vaccines Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2512-7919","authenticated-orcid":false,"given":"Nadine","family":"Rouphael","sequence":"additional","affiliation":[{"name":"Hope Clinic, Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine , Atlanta, Georgia ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana M","family":"El Sahly","sequence":"additional","affiliation":[{"name":"Departments of Molecular Virology and Microbiology and Medicine, Baylor College of Medicine , Houston, Texas ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernesto T A","family":"Marques","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Microbiology, University of Pittsburgh , Pittsburgh, Pennsylvania ,","place":["USA"]},{"name":"Funda\u00e7\u00e3o Oswaldo Cruz, Insituto Aggeu Magalh\u00e3es , Recife ,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9023-2339","authenticated-orcid":false,"given":"Albert I","family":"Ko","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Oswaldo Cruz, Instituto Gon\u00e7alo Moniz , Salvador ,","place":["Brazil"]},{"name":"Department of Epidemiology of Microbial Diseases, Yale School of Public Health , New Haven, Connecticut ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilo J","family":"Acosta","sequence":"additional","affiliation":[{"name":"Vaccines Business Unit, Takeda Vaccines Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"2025120309393482100_ofaf707-B1","author":"World Health Organization"},{"key":"2025120309393482100_ofaf707-B2","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2105\/AJPH.2016.303113","article-title":"The epidemic of Zika virus-related microcephaly in Brazil: detection, control, etiology, and future scenarios","volume":"106","author":"Teixeira","year":"2016","journal-title":"Am J Public Health"},{"key":"2025120309393482100_ofaf707-B3","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1056\/NEJMra1808246","article-title":"Zika virus infection - after the pandemic","volume":"381","author":"Musso","year":"2019","journal-title":"N Engl J Med"},{"key":"2025120309393482100_ofaf707-B4","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/M16-0332","article-title":"Emergence of congenital Zika syndrome: viewpoint from the front lines","volume":"164","author":"Costa","year":"2016","journal-title":"Ann Intern Med"},{"key":"2025120309393482100_ofaf707-B5","first-page":"100395","article-title":"Risk of adverse outcomes in offspring with RT-PCR confirmed prenatal Zika virus exposure: an individual participant data meta-analysis of 13 cohorts in the Zika Brazilian cohorts consortium","volume":"17","author":"de Alencar Ximenes","year":"2023","journal-title":"Lancet Reg Health Am"},{"key":"2025120309393482100_ofaf707-B6","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41426-018-0069-2","article-title":"Neurotropism and behavioral changes associated with Zika infection in the vector","volume":"7","author":"Gaburro","year":"2018","journal-title":"Emerg Microbes Infect"},{"key":"2025120309393482100_ofaf707-B7","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.coi.2018.04.024","article-title":"Zika virus vaccines: immune response, current status, and future challenges","volume":"53","author":"Richner","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"2025120309393482100_ofaf707-B8","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/infdis\/jiac482","article-title":"Persistence of immunogenicity of a purified inactivated Zika virus vaccine candidate in healthy adults: 2 years of follow-up compared with natural infection","volume":"227","author":"Acosta","year":"2023","journal-title":"J Infect Dis"},{"key":"2025120309393482100_ofaf707-B9","doi-asserted-by":"crossref","first-page":"e390","DOI":"10.1016\/S1473-3099(24)00794-1","article-title":"Zika virus: advancing a priority research agenda for preparedness and response","volume":"25","author":"Lackritz","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2025120309393482100_ofaf707-B10","doi-asserted-by":"crossref","first-page":"e402","DOI":"10.1016\/S1473-3099(24)00750-3","article-title":"Zika virus vaccines and monoclonal antibodies: a priority agenda for research and development","volume":"25","author":"Ostrowsky","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2025120309393482100_ofaf707-B11","doi-asserted-by":"crossref","first-page":"16509","DOI":"10.1038\/s41598-018-34735-7","article-title":"Purified inactivated Zika vaccine candidates afford protection against lethal challenge in mice","volume":"8","author":"Baldwin","year":"2018","journal-title":"Sci Rep"},{"key":"2025120309393482100_ofaf707-B12","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1038\/s41598-020-60415-6","article-title":"Complete protection in macaques conferred by purified inactivated Zika vaccine: defining a correlate of protection","volume":"10","author":"Young","year":"2020","journal-title":"Sci Rep"},{"key":"2025120309393482100_ofaf707-B13","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/S1473-3099(20)30733-7","article-title":"Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in healthy adults: an observer-blind, randomised, phase 1 trial","volume":"21","author":"Han","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2025120309393482100_ofaf707-B14","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.3390\/microorganisms12061177","article-title":"Predicting efficacy of a purified inactivated Zika virus vaccine in flavivirus-na\u00efve humans using an immunological correlate of protection in non-human primates","volume":"12","author":"Acosta","year":"2024","journal-title":"Microorganisms"},{"key":"2025120309393482100_ofaf707-B15","doi-asserted-by":"crossref","first-page":"e0003764","DOI":"10.1371\/journal.pntd.0003764","article-title":"High rate of subclinical chikungunya virus infection and association of neutralizing antibody with protection in a prospective cohort in the Philippines","volume":"9","author":"Yoon","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"2025120309393482100_ofaf707-B16","author":"Advisory Committee on Immunization Practices (ACIP) Chikungunya Vaccines Work Group"},{"key":"2025120309393482100_ofaf707-B17","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41564-023-01543-3","article-title":"Household immunity and individual risk of infection with dengue virus in a prospective, longitudinal cohort study","volume":"9","author":"Hamins-Pu\u00e9rtolas","year":"2024","journal-title":"Nat Microbiol"},{"key":"2025120309393482100_ofaf707-B18","doi-asserted-by":"crossref","first-page":"ofy352","DOI":"10.1093\/ofid\/ofy352","article-title":"Clinical, virologic, and immunologic characteristics of Zika virus infection in a cohort of US patients: prolonged RNA detection in whole blood","volume":"6","author":"El Sahly","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2025120309393482100_ofaf707-B19","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.3201\/eid2607.190846","article-title":"Transmission of chikungunya virus in an urban slum, Brazil","volume":"26","author":"Anjos","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"2025120309393482100_ofaf707-B20","doi-asserted-by":"crossref","first-page":"e0004275","DOI":"10.1371\/journal.pntd.0004275","article-title":"Spatiotemporal determinants of urban leptospirosis transmission: four-year prospective cohort study of slum residents in Brazil","volume":"10","author":"Hagan","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"2025120309393482100_ofaf707-B21","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ijid.2023.11.039","article-title":"Extensive transmission of SARS-CoV-2 BQ.1* variant in a population with high levels of hybrid immunity: a prevalence survey","volume":"139","author":"Aguilar Ticona","year":"2024","journal-title":"Int J Infect Dis"},{"key":"2025120309393482100_ofaf707-B22","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1126\/science.aav6618","article-title":"Impact of preexisting dengue immunity on Zika virus emergence in a dengue endemic region","volume":"363","author":"Rodriguez-Barraquer","year":"2019","journal-title":"Science"},{"key":"2025120309393482100_ofaf707-B23","doi-asserted-by":"crossref","first-page":"e0006055","DOI":"10.1371\/journal.pntd.0006055","article-title":"Zika virus displacement by a chikungunya outbreak in recife, Brazil","volume":"11","author":"Magalhaes","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"2025120309393482100_ofaf707-B24","doi-asserted-by":"crossref","first-page":"186","DOI":"10.4269\/ajtmh.21-1279","article-title":"Two-year decay of Zika virus neutralizing antibodies in people living in an endemic region in Brazil","volume":"107","author":"Magalhaes","year":"2022","journal-title":"Am J Trop Med Hyg"},{"key":"2025120309393482100_ofaf707-B25","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1093\/infdis\/jiw477","article-title":"Results of a Zika virus (ZIKV) immunoglobulin M-specific diagnostic assay are highly correlated with detection of neutralizing anti-ZIKV antibodies in neonates with congenital disease","volume":"214","author":"Cordeiro","year":"2016","journal-title":"J Infect Dis"},{"key":"2025120309393482100_ofaf707-B26","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/aje\/kwaa008","article-title":"An innovative, prospective, hybrid cohort-cluster study design to characterize dengue virus transmission in multigenerational households in Kamphaeng Phet, Thailand","volume":"189","author":"Anderson","year":"2020","journal-title":"Am J Epidemiol"},{"key":"2025120309393482100_ofaf707-B27","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1016\/j.vaccine.2023.04.015","article-title":"Impact of prior flavivirus vaccination on immunogenicity and efficacy of an inactivated Zika vaccine in Indian rhesus macaques","volume":"41","author":"Young","year":"2023","journal-title":"Vaccine"},{"key":"2025120309393482100_ofaf707-B28","doi-asserted-by":"crossref","first-page":"e0250516","DOI":"10.1371\/journal.pone.0250516","article-title":"A high throughput reporter virus particle microneutralization assay for quantitation of Zika virus neutralizing antibodies in multiple species","volume":"16","author":"Bohning","year":"2021","journal-title":"PLoS One"},{"key":"2025120309393482100_ofaf707-B29","doi-asserted-by":"crossref","first-page":"e48460","DOI":"10.7554\/eLife.48460","article-title":"Zika seroprevalence declines and neutralizing antibodies wane in adults following outbreaks in French Polynesia and Fiji","volume":"9","author":"Henderson","year":"2020","journal-title":"Elife"},{"key":"2025120309393482100_ofaf707-B30","doi-asserted-by":"crossref","first-page":"1081107","DOI":"10.3389\/fimmu.2022.1081107","article-title":"Recent updates on correlates of vaccine-induced protection","volume":"13","author":"Plotkin","year":"2022","journal-title":"Front Immunol"},{"key":"2025120309393482100_ofaf707-B31","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.3390\/microorganisms12071492","article-title":"Immunological and safety considerations when selecting the dose formulation of a purified inactivated Zika virus vaccine (PIZV)","volume":"12","author":"Acosta","year":"2024","journal-title":"Microorganisms"},{"key":"2025120309393482100_ofaf707-B32","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1126\/science.abb6143","article-title":"Zika virus infection enhances future risk of severe dengue disease","volume":"369","author":"Katzelnick","year":"2020","journal-title":"Science"},{"key":"2025120309393482100_ofaf707-B33","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1126\/science.aal4365","article-title":"Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity","volume":"356","author":"Bardina","year":"2017","journal-title":"Science"},{"key":"2025120309393482100_ofaf707-B34","doi-asserted-by":"crossref","first-page":"13498","DOI":"10.1038\/s41598-019-49569-0","article-title":"High correlation between Zika virus NS1 antibodies and neutralizing antibodies in selected serum samples from normal healthy Thais","volume":"9","author":"Sornjai","year":"2019","journal-title":"Sci Rep"},{"key":"2025120309393482100_ofaf707-B35","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/infdis\/jiaa132","article-title":"Dengue endemicity, force of infection, and variation in transmission intensity in 13 endemic countries","volume":"225","author":"Nealon","year":"2022","journal-title":"J Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/12\/ofaf707\/65727617\/ofaf707.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/12\/ofaf707\/65727617\/ofaf707.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T14:39:49Z","timestamp":1764772789000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaf707\/8363724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,11,26]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaf707","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,11,26]]},"article-number":"ofaf707"}}